[Inhibition of ovulation with 17-alpha-ethinyl-18-methyl-11-methylene-4-estren-17-ol plus ethinylestradiol].
A combined oral application of 30 micrograms ethinylestradiol with 50 micrograms 17 alpha-ethinyl-18-methyl-11-methylene-4-estren-17-ol (a newly developed progestagen) -- for 21 days resulted in a distinct antigonadotrophic effect, shown by hormone analysis (LH, FSH, estradiol and progesterone) in serum samples of three healthy and fertile women. A final recommendation on the daily dosage, however, depends on the results of clinical experimental investigation still in progress.
D004958:Estradiol / Q000097:blood; D004963:Estrenes; D004997:Ethinyl Estradiol; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006718:Homosteroids; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D010053:Ovary / Q000187:drug effects / Q000502:physiology; D010060:Ovulation / Q000187:drug effects*; D011374:Progesterone / Q000097:blood; D045167:Progesterone Congeners
D004963:Estrenes; D006718:Homosteroids; D045167:Progesterone Congeners; D004997:Ethinyl Estradiol; D011374:Progesterone; D004958:Estradiol; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone
Zur Ovulationshemmung mit 17 alpha-Athinyl-18-methyl-11-methylen-4-östren-17-ol plus Athinylöstradiol.